Why “PFAS-Free” Claims Need More Definition

The problem is not that suppliers are testing. Testing is necessary, and total fluorine screening can be a useful part of a broader evidence package. The problem begins when a specific result, generated by a specific method, on a specific material, with a specific reporting limit, gets converted into an absolute statement. “Not detected” does not mean none. “Below threshold” does not mean absent. “No intentionally added PFAS” does not mean no possible fluorinated residue, contamination, or legacy supply-chain contribution.

PFAS is not one chemical. It is a broad class of fluorinated substances, with different definitions across regulatory and industry frameworks. Some PFAS are small molecules that can be measured directly through targeted methods. Others are polymeric, embedded in materials, or difficult to capture through conventional testing. That complexity does not make PFAS testing meaningless. It makes method, scope, and detection limit essential.

This is where some of the current confusion begins. In textiles and apparel, total fluorine or total organic fluorine thresholds have become part of certain PFAS compliance frameworks. A 100 ppm threshold may help determine whether a fabric, coating, or finish meets a particular regulatory requirement. But that does not make 100 ppm a universal definition of “PFAS-Free” for a diagnostic analyzer, a catheter component, a vial cap liner, a reagent-contact gasket, or a bioprocessing fluid path.

A rain jacket and an IVD fluidic system are not the same risk environment, even if both may be discussed using the same fluorine threshold. In IVD, a material can affect assay performance even when there is no direct patient exposure. A vial cap liner used in sample preparation can become part of the contamination-control system. A reagent bottle seal can interact with buffers, surfactants, solvents, enzymes, or preservatives. A pump tube can influence flow accuracy, absorption, evaporation, and leachables. A diagnostic cartridge gasket can affect compression set, sealing force, particulate generation, and sample integrity.

In medical devices, the risk question changes again. Is the material patient-contacting, fluid-path, drug-contacting, or used only during manufacturing? Is it exposed to sterilization, aging, cleaning agents, contrast media, saline, blood, or tissue? Is the concern patient exposure, extractables and leachables, mechanical reliability, regulatory compliance, or customer preference? A PFAS-related claim that may be adequate for secondary packaging may not be adequate for a patient-contacting or fluid-path component.

That is why the question should not be, “Is it PFAS-Free?” The better question is, “What exactly is being claimed, and what evidence supports it?”

A useful supplier claim should start with definition. What does the supplier mean by PFAS? Is the claim based on a regulatory definition, a restricted substances list, an internal formulation policy, or a third-party certification framework from another industry? Different definitions may capture different chemistries, so the word “PFAS” needs a boundary before the claim can be evaluated.

Scope is just as important. Was the finished component tested, or only the raw material? Does the claim apply to the whole part, or only one layer? Does it include films, liners, adhesives, colorants, lubricants, mold releases, processing aids, packaging, and secondary materials? In medical and IVD systems, the highest-risk material is not always the largest material by mass. A thin liner, coating, adhesive, or processing residue can matter more than the bulk polymer if it sits in the fluid path or contacts the sample.

Method matters too. A targeted PFAS panel is not the same as total fluorine testing. Total fluorine is not the same as total organic fluorine. Extractables testing is not the same as a universal PFAS screen. Each method answers a different question, and none of them should be asked to prove more than it can actually support.

Detection limit is the part of the claim that is easiest to overlook and hardest to ignore. In analytical testing, “not detected” means not detected above the method’s reporting limit under the conditions of that test. It does not mean zero. A non-detect result may be perfectly appropriate for one screening purpose and insufficient for another, especially in diagnostic applications where low-level contamination, adsorption, or leachables can affect assay performance.

The target list also matters. Testing for a defined panel of PFAS compounds can be valuable, but a targeted panel is not the same as testing for every possible PFAS. It tells the customer that specific compounds were not detected above stated reporting limits. That may be an important part of the evidence package, but it should not be rounded up into proof that no PFAS-related substance exists anywhere in the material system.

Why “No Intentionally Added PFAS” May Be More Useful

This is why “no intentionally added PFAS” is often more technically useful than “PFAS-Free.” It says something specific about formulation and supply-chain intent. It can be supported through supplier declarations, raw material review, formulation controls, and change management. When paired with appropriate testing, it gives medical device and IVD manufacturers a clearer basis for risk assessment.

Evaluating Fluoropolymer Alternatives Requires Application-Specific Validation

In many applications, “fluoropolymer alternative” may be even more precise. That phrase does not pretend the issue is solved by a label. It identifies the design challenge: replacing PTFE, FEP, PFA, ETFE, PVDF, or another fluorinated material with a different material system that still has to perform. That replacement may be the right decision, but it still has to meet the requirements that made the original material attractive in the first place, including chemical resistance, low surface energy, cleanliness, thermal stability, low friction, durability, processability, and dimensional control.

A non-fluorinated alternative is not automatically lower risk. It is a different risk profile. Removing a fluorinated material can reduce one set of concerns while introducing another. A new elastomer may swell in reagent. A new liner may adsorb analyte. A new tubing material may shift pump calibration. A new seal may pass initial compatibility but fail after sterilization or aging. A new film may reduce fluorine content but increase extractables.

That is the part a simple claim can hide. Medical and diagnostic systems rarely reward substitution by label alone. They require application-specific validation, because the cleanest wording is not always the cleanest engineering decision.

For medical device and IVD manufacturers, the better path is disciplined substitution. Start with the application. Define the exposure. Identify whether the concern is patient safety, assay interference, contamination control, regulatory compliance, customer preference, or supply-chain resilience. Then decide what evidence is needed to support the material decision.

A strong PFAS-related supplier statement should answer practical questions clearly.

• What PFAS definition is being used?
• Does the claim mean no intentionally added PFAS, below-threshold fluorine, non-detect targeted PFAS, or something else?
• Which material or component was tested?
• Was the finished article tested, or only raw material?
• What method was used? What were the reporting limits?
• Which analytes were included?
• Were sterilized, aged, or use-conditioned samples evaluated?
• What supplier controls prevent the claim from changing when a formulation, processing aid, or upstream source changes?

That last question is critical. PFAS communication is not only a testing issue. It is a change-control issue. A test report from one lot can be useful, but medical and diagnostic manufacturers need confidence that the material story will remain true over time.

The Bottom Line: Precision Matters More Than the Label

The PFAS transition is real. Customers are right to ask harder questions, and suppliers should be ready to answer them. But the answer should not be a vague claim borrowed from another industry and stretched beyond what the data can support.

Medical and IVD materials deserve more precise language. “PFAS-Free” may fit on a brochure, but the real question is whether the claim is defined tightly enough to survive qualification, audit, change control, and real use. In this market, that is the standard that matters.